Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases

• Published in: The Lancet infectious diseases Vol. 22; no. 7; pp. e178 - e190
• Main Authors: Lange, Christoph, Böttger, Erik C, Cambau, Emmanuelle, Griffith, David E, Guglielmetti, Lorenzo, van Ingen, Jakko, Knight, Shandra L, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, Wagner, Dirk, Winthrop, Kevin, Daley, Charles L, Andrejak, Claire, Böttger, Erik, Griffith, David, Knight, Shandra, Leitman, Philip, Marras, Theodore K., Olivier, Kenneth N., Stout, Jason E., Wallace, Richard J., Daley, Charles
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.07.2022; Elsevier Limited; New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001
• Subjects: Antibiotics; Bacteriology; Case reports; Chronic obstructive pulmonary disease; Clinical microbiology; Clinical trials; Cystic fibrosis; Drugs; Health services; HIV; Human immunodeficiency virus; Infectious diseases; Life Sciences; Literature reviews; Lung diseases; Microbiology; Microbiology and Parasitology; Motility; Mycobacterium; Organisms; Systematic review; Thorax; Tuberculosis
• ISSN: 1473-3099; 1474-4457
• DOI: 10.1016/S1473-3099(21)00586-7

The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America; and the 2017 management guideline by the British Thoracic Society covered pulmonary diseases in adults caused by Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium xenopi, and Mycobacterium abscessus. In order to provide evidence-based recommendations for the treatment of less common non-tuberculous mycobacterial (NTM) species in adult patients without cystic fibrosis or HIV infection, our expert panel group performed systematic literature searches to provide management guidance for pulmonary diseases caused by seven additional organisms: Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium malmoense, Mycobacterium simiae, and Mycobacterium szulgai. Treatment recommendations were developed by a structured consensus process. The evidence from the scientific literature published in English for treatment recommendations for pulmonary diseases caused by other NTM species was of very low quality, with the exception of M malmoense, and based on the evaluation of case reports and case series. For M malmoense, results from two randomised controlled trials and three retrospective cohort studies provided a better evidence base for treatment recommendations, although the evidence was still of low quality.